title: Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor.
abstract: Isoproterenol (ISO) and forskolin, agents that increase adenosine 3',5'-cyclic monophosphate (cAMP) via adenylyl cyclase activation, reverse lung injury associated with increased microvascular permeability. We studied the role of rolipram, a relatively isozyme-selective cAMP phosphodiesterase (PDE) inhibitor, in reversing increased capillary permeability due to ischemia-reperfusion (I/R), a form of oxidant injury in the lung, by using the isolated perfused rat lung model. Rolipram (2 microM) administered after 45 min of ischemia and 45 min of reperfusion reduced I/R-increased permeability as measured by the capillary filtration coefficient to control lung values. Computer image analysis of air space edema and perivascular cuffing, as well as wet-to-dry weight ratios, confirms the permeability reversal by rolipram administration. Rolipram inhibition of cAMP PDE in the lung was assessed by using [3H]adenine prelabeling adapted for the whole lung and perfusate [3H]cAMP accumulation. Rolipram failed to increase perfusate cAMP alone but dramatically increased perfusate cAMP above ISO alone. Dose-response relationships of ISO or rolipram show a close correlation of the half-maximal effective dose (ED50) for injury reversal and perfusate cAMP production. The combination of rolipram and ISO produced synergistic reversal of I/R injury. We conclude that reversal of I/R-induced increased microvascular permeability can be achieved with rolipram and that the mechanism of action of rolipram is probably through PDE isozyme-selective inhibition. The similarity of the ED50 values for cAMP efflux and reversal of permeability increases also supports a close coupling between cAMP accumulation and endothelial cell permeability.
authors.affiliation: Department of Pharmacology, Rush Medical School, Chicago, Illinois 60612.
authors.forename: J W
authors.initials: JW
authors.lastname: Barnard
authors.forename: A F
authors.initials: AF
authors.lastname: Seibert
authors.forename: V R
authors.initials: VR
authors.lastname: Prasad
authors.forename: D A
authors.initials: DA
authors.lastname: Smart
authors.forename: S J
authors.initials: SJ
authors.lastname: Strada
authors.forename: A E
authors.initials: AE
authors.lastname: Taylor
authors.forename: W J
authors.initials: WJ
authors.lastname: Thompson
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000225:Adenine / Q000378:metabolism; D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects; D005576:Colforsin / Q000494:pharmacology; D007091:Image Processing, Computer-Assisted; D007545:Isoproterenol / Q000494:pharmacology; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008297:Male; D011652:Pulmonary Circulation / Q000187:drug effects; D011760:Pyrrolidinones / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000473:pathology; D020889:Rolipram
chemical_list: D011760:Pyrrolidinones; D005576:Colforsin; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D000262:Adenylyl Cyclases; D000225:Adenine; D020889:Rolipram; D007545:Isoproterenol